| Literature DB >> 35335950 |
Neha Raina1, Rakesh Pahwa2, Jaydeep Bhattacharya3, Alok K Paul4, Veeranoot Nissapatorn5, Maria de Lourdes Pereira6,7, Sonia M R Oliveira6,8, Karma G Dolma9, Mohammed Rahmatullah10, Polrat Wilairatana11, Madhu Gupta1.
Abstract
Hydrogels are a promising and attractive option as polymeric gel networks, which have immensely fascinated researchers across the globe because of their outstanding characteristics such as elevated swellability, the permeability of oxygen at a high rate, good biocompatibility, easy loading, and drug release. Hydrogels have been extensively used for several purposes in the biomedical sector using versatile polymers of synthetic and natural origin. This review focuses on functional polymeric materials for the fabrication of hydrogels, evaluation of different parameters of biocompatibility and stability, and their application as carriers for drugs delivery, tissue engineering and other therapeutic purposes. The outcome of various studies on the use of hydrogels in different segments and how they have been appropriately altered in numerous ways to attain the desired targeted delivery of therapeutic agents is summarized. Patents and clinical trials conducted on hydrogel-based products, along with scale-up translation, are also mentioned in detail. Finally, the potential of the hydrogel in the biomedical sector is discussed, along with its further possibilities for improvement for the development of sophisticated smart hydrogels with pivotal biomedical functions.Entities:
Keywords: biomedical perspectives; clinical trials; contact lenses; drug delivery; hydrogels; therapeutic interventions; tissue engineering; translation; wound management
Year: 2022 PMID: 35335950 PMCID: PMC8950534 DOI: 10.3390/pharmaceutics14030574
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Hydrogel structural chemistry [50].
Figure 2Physical crosslinking techniques.
Figure 3Evaluation parameters of hydrogels.
Hydrogel loaded with various active ingredients.
| Therapeutically Active Substances/Drugs | Polymers/ Monomers | Method/Mechanism | Inference | References |
|---|---|---|---|---|
| Adipose stem cells | Hyaluronic acid | Ultraviolet irradiation | Promising carrier for stem cell delivery in wound repair and skin tissue engineering | [ |
| Vancomycin | Agarose | Hydrogen bonding | Potential candidate for healing of infected wounds | [ |
| Catechol | Chitosan | Covalent bonding | Designed system utilized successfully for buccal drug delivery | [ |
| Diacerein | Polyethylene glycol | Hydrophobic interactions | Hydrogel successfully repaired spinal cord injury | [ |
| Heparin | Poloxamer 407 | Cold method | Delivery system provided release in controlled manner and can be employed for nerve regeneration | [ |
Figure 4Mechanisms of drug release from hydrogel.
Recent patents on hydrogels.
| Patent No | Title | Highlights | Date |
|---|---|---|---|
| US20210023121A1 | Thrombin-responsive hydrogels and devices for auto-anticoagulant regulation | Compounds, compositions, devices, and methods for auto-anticoagulation regulation. Further disclosed methods for treating or preventing thrombosis | 28 January2021 |
| US20200206030A1 | High-precision drug delivery by dual-domain ocular device | Nanocomposite ocular device provided controlled and sustained release of the drug | 2 July 2020 |
| US20200214882A1 | Treating conditions caused by abnormal growth of pathogens in body cavities | The invention based on cooling or temperature reducing treatment device to cure vaginal infections, including vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), and to reduce biofilms | 9 July 2020 |
| US20200214886A1 | Programmable therapeutic agent delivery from eye mounted device | Systems and methods for on-demand delivery of a therapeutic agent from an eye mounted device | 9 July 2020 |
| US20200214887A1 | Eye mounted device for therapeutic agent release | Devices and systems for targeted and controlled delivery of a therapeutic agent to a treatment site of an eye | 9 July 2020 |
| US20200215136A1 | Medication dispensing system | Method disclosed for providing treatment with cannabis to treat insomnia, anxiety, or seizure, among others | 9 July 2020 |
| US20200215194A1 | Apoptosis inhibitor formulations for prevention of hearing loss | Formulation for sustained release of an apoptosis inhibitor in the inner ear to protect from hearing loss, especially due to exposure to chemotherapy with drugs such as cisplatin | 9 July 2020 |
| US20200282062A1 | Medication | Method of treating seizure, insomnia, or anxiety includes administering, via a patch, pill, lotion, mist, or hydrogel to humans | 10 September 2020 |
| US20200316052A1 | Ophthalmic composition | Methods of arresting or preventing myopia development by administering to an eye of an individual an effective amount of an ophthalmic composition | 27 September 2020 |
| US20200330380A1 | Biocompatible organogel matrices for intraoperative preparation of a drug delivery depot | Disclosure directed to an organogel drug depot for use in delivering an active agent to a surgical site, such as an orthopedic implant site | 22 October 2020 |
Clinical trials on hydrogels.
| Condition | Hydrogel | Clinical Trial Number | Status | Reference |
|---|---|---|---|---|
| Osteoarthritis, knee | Hydrogel injection | NCT04061733 | Recruiting | [ |
| Ruptured aneurysm | Second-generation hydrogel coils | NCT03252314 | Recruiting | [ |
| Wound infection, surgical | Pico® negative pressure dressing, Aquacel Surgical® hydrogel dressing | NCT04265612 | Recruiting | [ |
| Refractive error-myopia bilateral | Hioxifilcon A standard hydrogel contact lens with hyaluronic acid (HA) | NCT04671108 | Recruiting | [ |
| Wound healing | 3% sodium pentaborate pentahydrate | NCT02241811 | Recruiting | [ |
| Mucositis oral, | MucoLox, sodium bicarbonate | NCT03461354 | Recruiting | [ |
| hypervascular tumors | Instylla HES, TAE or cTACE | NCT04523350 | Recruiting | [ |
| osteoarthritis, knee | PAAG-OA, Synvisc-One | NCT04045431 | Recruiting | [ |
| myopia | OxyAqua, Si-Hy | NCT03139201 | Completed | [ |
| Cancer of the prostate | PEG hydrogel (SpaceOAR) | NCT02212548 | Completed | [ |
| Cerebral aneurysm | Hydro coil embolic system, control (bare platinum coils) | NCT01407952 | Completed | [ |
| Astigmatism | verofilcon atoric contact lenses | NCT04464044 | Completed | [ |
| Knee osteoarthritis | PVA hydrogel, Synvisk-One® | NCT04693104 | Completed | [ |
| Bladder carcinoma | Polyethylene glycol hydrogel | NCT03125226 | Completed | [ |
| Myopia | Somofilcon A, | NCT03098745 | Completed | [ |
| Ametropia | Methafilcon A toric contact lenses, | NCT03835221 | Completed | [ |
| Intracranial aneurysm | Hydrogel coil, | NCT01516658 | Completed | [ |
Figure 5Drug-loaded contact lens hydrogel [201].
Figure 6Benefits of hydrogel in wound healing.
Figure 7Hydrogel in bone tissue engineering [219].